Jinxin Fertility Group Ltd. (1951) AI Stock Analysis

• Market Cap: HK$8.26B
• Dividend Yield: 1.98%
• Average Volume (3M): 59.57M
• Price to Earnings (P/E): 26.3
• Beta (1Y): 1.42
• Revenue Growth: -1.04%
• EPS Growth: -20.43%
• Country: HK
• Employees: 3,198
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Care Facilities
• EPS (TTM): 0.03
• Shares Outstanding: 2,757,706,000
• 10 Day Avg. Volume: 74,573,986
• 30 Day Avg. Volume: 59,565,183
• PEG Ratio: -2.01
• Price to Book (P/B): 1.84
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -38.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$3.80
• Price Target Upside: 26.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Outperform
• Price Target: HK$3.00 ▼(-0.33%Downside)

The overall stock score of 70.1 reflects Jinxin Fertility Group's strong financial performance, which is the most significant factor, alongside a stable technical outlook. Valuation is moderate, indicating a fairly priced stock with a reasonable dividend yield. The absence of recent earnings call insights and corporate events did not impact the score.

Jinxin Fertility Group Ltd. Business Overview & Revenue Model

Company Description

Jinxin Fertility Group Ltd. (1951) is a leading provider of assisted reproductive services based in China. The company operates in the healthcare sector, focusing primarily on fertility treatment services, including in vitro fertilization (IVF) and related services. Jinxin Fertility Group is recognized for its comprehensive suite of services aimed at addressing infertility issues, leveraging advanced medical technologies and expertise to support couples seeking to conceive.

How the Company Makes Money

Jinxin Fertility Group Ltd. generates revenue primarily through its assisted reproductive services, with in vitro fertilization (IVF) being the core service offering. The company earns money by providing a range of fertility treatments, which include medical consultations, diagnostic services, laboratory procedures, and the actual IVF processes. Additionally, Jinxin Fertility may have partnerships with hospitals and clinics, enhancing its service reach and client base. Revenue is largely driven by the demand for fertility services in China and potentially in other regions where the company operates, supported by factors such as increasing infertility rates, advancements in reproductive technology, and growing social acceptance of assisted reproductive techniques.

Jinxin Fertility Group Ltd. Financial Statement Overview

Summary

Jinxin Fertility Group demonstrates a strong financial position with consistent revenue growth, solid profitability, and efficient cash flow management. The balance sheet shows prudent leverage and strong equity, while operational efficiency is reflected in healthy margins and cash flow metrics.

Income Statement

Jinxin Fertility Group has shown consistent revenue growth over the years, with a notable increase in total revenue from 2020 to 2024. The gross profit margin has slightly decreased recently, indicating rising costs or pricing pressures. However, the company maintains healthy EBIT and EBITDA margins, demonstrating efficient operations and profitability.

Balance Sheet

The company has a strong equity base with a favorable debt-to-equity ratio, indicating prudent financial leverage. The return on equity remains strong, reflecting effective use of shareholders' funds. The equity ratio has increased over the years, highlighting a solid financial foundation and asset management.

Cash Flow

Operating cash flow has been positive and growing, supporting ongoing operations. The free cash flow, although fluctuating, has improved recently, enhancing financial flexibility. The operating cash flow to net income ratio is robust, indicating strong cash earnings conversion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.81B	2.79B	2.36B	1.84B	1.43B
Gross Profit	1.10B	1.18B	913.13M	771.48M	565.78M
EBITDA	645.06M	682.02M	476.21M	494.08M	331.91M
Net Income	283.10M	344.72M	121.12M	339.90M	251.62M
Balance Sheet
Total Assets	14.98B	14.90B	15.23B	12.83B	9.16B
Cash, Cash Equivalents and Short-Term Investments	570.82M	852.90M	1.40B	1.93B	2.47B
Total Debt	2.71B	2.55B	4.16B	2.09B	406.87M
Total Liabilities	4.63B	4.71B	6.50B	4.07B	1.70B
Stockholders Equity	10.27B	10.09B	8.64B	8.55B	7.28B
Cash Flow
Free Cash Flow	489.30M	510.92M	-417.65M	263.62M	41.89M
Operating Cash Flow	629.20M	684.48M	541.74M	343.45M	308.04M
Investing Cash Flow	-293.27M	-375.04M	-1.38B	-1.57B	1.15B
Financing Cash Flow	-458.29M	-950.45M	460.14M	955.05M	-55.58M

Jinxin Fertility Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1951, the sentiment is Positive. The current price of 3.01 is above the 20-day moving average (MA) of 2.99, above the 50-day MA of 2.92, and above the 200-day MA of 2.94, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 52.85 is Neutral, neither overbought nor oversold. The STOCH value of 72.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1951.

Jinxin Fertility Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2373	76 Outperform	HK$6.81B	26.84	26.24%	1.63%	17.69%	5.37%
1951	70 Outperform	HK$8.26B	26.29	2.78%	1.98%	-1.04%	-20.43%
6078	68 Neutral	HK$9.41B	14.86	9.30%	―	7.28%	-13.77%
2273	67 Neutral	HK$8.10B	25.02	13.13%	2.39%	28.02%	19.41%
1526	66 Neutral	HK$1.70B	5.28	24.13%	4.21%	-3.85%	-19.28%
Sector *	60 Neutral	HK$15.71B	5.67	-7.43%	4.09%	11.60%	-21.06%
3309	54 Neutral	HK$2.30B	33.92	-7.51%	1.09%	-0.56%	-323.09%

Jinxin Fertility Group Ltd. Corporate Events

Jinxin Fertility Group Ltd. Announces AGM Results and Committee Changes

Jinxin Fertility Group Ltd. held its Annual General Meeting on June 26, 2025, where all proposed resolutions were approved by poll. Key resolutions included the adoption of the company’s audited financial statements for 2024, re-election of several directors, and the re-appointment of Deloitte Touche Tohmatsu as the company’s auditor. These decisions reflect the company’s ongoing commitment to maintaining strong governance and financial transparency, which are crucial for its stakeholders and market positioning.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.

Jinxin Fertility Group Announces Board Composition and Roles

Jinxin Fertility Group Limited has announced the composition of its board of directors and the roles and functions of each member. The board includes executive, non-executive, and independent non-executive directors, with various members serving on five established committees. This announcement reflects the company’s structured governance approach and may impact its strategic decision-making and operational oversight.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.

Jinxin Fertility Group Announces 2025 Annual General Meeting

Jinxin Fertility Group Ltd. has announced its upcoming annual general meeting scheduled for June 26, 2025, in Chengdu, China. The meeting will address several key resolutions, including the adoption of the 2024 financial statements, re-election of directors, and re-appointment of Deloitte Touche Tohmatsu as auditors. Additionally, the company seeks shareholder approval to authorize the board to issue new shares and fix director remuneration, indicating a focus on strategic growth and governance.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.